Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Key Highlights
- ➤FDA feedback on new brilaroxazine formulation expected in Q4 2026
- ➤RECOVER-2 Phase 3 enrollment targeted for 1H 2027, subject to financing
- ➤Patent application could extend brilaroxazine protection through 2046
- ➤Q3 net loss narrowed to $2.3 million from $4.0 million year over year
- ➤Cash and equivalents rose to approximately $17.5 million at September 30, 2026
Expert Statements
Laxminarayan Bhat, Founder, President, and CEO of Reviva Pharmaceuticals
“Our near-term focus is obtaining Food and Drug Administration (FDA) feedback on the proposed use of a new formulation of brilaroxazine and preparing for the next stages of clinical development while managing our capital resources carefully”
Laxminarayan Bhat, Founder, President, and CEO of Reviva Pharmaceuticals
“We expect FDA feedback in the fourth quarter of 2026 to inform the use of this formulation in our RECOVER-2 registrational Phase 3 trial and a future New Drug Application (NDA) submission for the treatment of schizophrenia.”
Laxminarayan Bhat, Founder, President, and CEO of Reviva Pharmaceuticals
“Following that feedback, we plan to initiate a bioequivalence study to confirm comparability of the new formulation in the first quarter of 2027.”
Laxminarayan Bhat, Founder, President, and CEO of Reviva Pharmaceuticals
“We also target initiation of RECOVER-2 patient enrollment in the first half of 2027, subject to receipt of additional financing.”
Laxminarayan Bhat, Founder, President, and CEO of Reviva Pharmaceuticals
“In parallel, we have filed a composition of matter patent application for the new formulation of brilaroxazine, with the potential to extend patent protection through 2046.”
Laxminarayan Bhat, Founder, President, and CEO of Reviva Pharmaceuticals
“We remain focused on disciplined execution as we advance brilaroxazine as a potentially differentiated treatment option for patients with schizophrenia.”
- FDA feedback expected in Q4 2026 on proposed use of new formulation of brilaroxazine in the RECOVER-2 trial and a future NDA submission -
- U.S. patent office has granted priority examination (Track 1) for the composition of matter patent application filed covering new formulation of brilaroxazine, with potential to extend patent protection through 2046 –
Get started
Create a free account to read the full story.